Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

Published 2017 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
Authors
Keywords
afatinib, EGFR mutation-positive, first-line therapy, lung adenocarcinoma, real-world study
Journal
Oncotarget
Volume 8, Issue 52, Pages -
Publisher
Impact Journals, LLC
Online
2017-07-27
DOI
10.18632/oncotarget.19563

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.